Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 May 1.

Published in final edited form as: Int J Cancer. 2010 May 1;126(9):2112–2122. doi: 10.1002/ijc.24909

Dopamine secretion in cholangiocarcinoma. Dopamine levels in bile samples from cholangiocarcinoma patients and patients with intrahepatic cholelithiasis were determined by EIA (A). Data are expressed in a scatter plot of dopamine concentration (ng/mL left axis and nMol right axis). Dopamine immunoreactivity was assessed in biopsy samples from 48 cholangiocarcinoma patients and 4 healthy controls by immunohistochemistry (upper panel) and in paraffin-embedded sections containing cholangiocarcinoma and the surrounding non-malignant liver tissue (n=6; lower panel). Representative photomicrographs of the dopamine immunoreactivity are shown (B; magnification X40). Staining intensity was assessed as described in the methods. P values and the power analysis values are shown in parentheses.

Dopamine secretion in cholangiocarcinoma. Dopamine levels in bile samples from cholangiocarcinoma patients and patients with intrahepatic cholelithiasis were determined by EIA (A). Data are expressed in a scatter plot of dopamine concentration (ng/mL left axis and nMol right axis). Dopamine immunoreactivity was assessed in biopsy samples from 48 cholangiocarcinoma patients and 4 healthy controls by immunohistochemistry (upper panel) and in paraffin-embedded sections containing cholangiocarcinoma and the surrounding non-malignant liver tissue (n=6; lower panel). Representative photomicrographs of the dopamine immunoreactivity are shown (B; magnification X40). Staining intensity was assessed as described in the methods. P values and the power analysis values are shown in parentheses.